UPDATE 1-Sanofi wins EU approval for second MS treatment
* Sanofi to launch Lemtrada, Aubagio in EU soon
* Still awaiting Lemtrada approval from U.S. FDA (Adds background)
PARIS, Sept 17 (Reuters) - French drugmaker Sanofi said it won approval from European authorities for a second multiple sclerosis treatment, paving the way to start selling both drugs in the region soon.
The marketing authorisation for injectable drug Lemtrada from the European Commission follows a similar green light for MS pill Aubagio on Aug. 30, Sanofi said in a statement on Tuesday.
"The company intends to begin launching both products in the EU soon," Sanofi said.
The endorsement by the Commission followed positive recommendations from the European Medicines Agency earlier this year. The U.S. Food and Drug Administration is expected to rule on Lemtrada in late 2013. Aubagio won U.S. approval a year ago.
Multiple sclerosis is a chronic, often disabling disease that attacks the central nervous system and can lead to numbness, paralysis and loss of vision. MS is estimated to affect more than 2.1 million people globally, with about 630,000 people affected in Europe, according to Sanofi. (Reporting by James Regan; Editing by David Cowell)
- Exclusive: Angry with Washington, 1 in 4 Americans open to secession
- U.S. immigration protesters drop U.S. border blockade plan
- About 60,000 Syrian Kurds flee to Turkey from Islamic State advance |
- Secret Service investigates after man jumps White House fence, reaches doors
- Kentucky firefighter dies after ice bucket challenge accident